Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.10.3322/caac.2007320610543Search in Google Scholar

Brawley OW, Ankerst DP, Thompson IM. Screening prostate cancer. CA Cancer Clin 2009; 59: 264-73.10.3322/caac.2002619564245Search in Google Scholar

Albersen PC. A challenge to contemporary management of prostate cancer. Nat Clin Pract Urol 2009; 6: 12-3.10.1038/ncpuro127019065140Search in Google Scholar

Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Abdullah RSAR. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43: 180-6.10.2478/v10019-009-0023-ySearch in Google Scholar

Rojnik M, Jevnikar Z, Mirkovic B, Janes D, Zidar N, Kikelj D, et al. Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines. Radiol Oncol 2011; 45: 259-66.10.2478/v10019-011-0034-3342375022933963Search in Google Scholar

Ben-Haim S, Ell P. 18f-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med 2009; 50: 88-99.10.2967/jnumed.108.05420519139187Search in Google Scholar

Farsad M, Schiavina R, Franceschelli A, Sanguedolce F, Castellucci P, Bertaccini A, et al. Positron emission tomography in imaging and staging prostate cancer. Cancer Biomarkers 2008; 4: 277-84.10.3233/CBM-2008-44-50918957716Search in Google Scholar

Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008; 134: 227-36.10.1007/s00432-007-0275-017653575Search in Google Scholar

Gu J, Yamamoto H, Fukunaga H, Danno K, Takemasa I, Ikeda M, et al. Correlation of Glut-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006; 51: 2198-205.10.1007/s10620-006-9428-217080242Search in Google Scholar

Ueda S, Kondoh N, Tsuda H, Yamamoto S, Asakawa H, Fukatsu K, et al. Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer 2008; 8: 384.10.1186/1471-2407-8-384263159119102762Search in Google Scholar

Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg 2009; 15: 304-10.Search in Google Scholar

Backes H, Ullrick R, Neumaier B, Kracht L, Wienhard K, Hacobs AH. Noninvasive quantification of tumour proliferation in patients with high-grade glioma. Eur J Nucl Mol Imaging 2009; 36: 1960-7.10.1007/s00259-009-1244-4Search in Google Scholar

Kawai N, Zhen HN, Miyake K, Yamamaoto Y, Nishiyama Y, Tamiya T. Prognostic value of pretreatment 18F-FDG PET in patients with primary central system lymphoma: SUV-based assessment. J Neuroncol 2010; 100: 225-32.10.1007/s11060-010-0182-0Search in Google Scholar

American Joint Committee on Cancer. Prostate. In: Greene FL, Page DL, Fleming ID, editors. AJCC Cancer staging manual. 6th edition. New York: Springer; 2002. p. 309-16.10.1007/978-1-4757-3656-4_34Search in Google Scholar

Li X, Liu Q, Wang M, Jin X, Liu Q, Yao S, et al. C-11 choline PET/CT imaging for differenting malignant from benign prostate lesions. Clin Nucl Med 2008; 10: 671-6.10.1097/RLU.0b013e318184b3a0Search in Google Scholar

Shukla-Dave A, Hricak H, Ishill N, Moskowitz CS, Drobnjak M, Reuter VE, et al. Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles. Clin Cancer Res 2009; 15: 3842-9.10.1158/1078-0432.CCR-08-2453Search in Google Scholar

Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113: 619-28.10.1002/ijc.20615Search in Google Scholar

Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, et al. Long term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate 2008; 68: 1806-15.10.1002/pros.20848Search in Google Scholar

Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial fingdings of PET with 2-deoxy-2[F-18]fluoro-D-glucose. Radiology 1996; 199: 751-6.10.1148/radiology.199.3.8638000Search in Google Scholar

Hodolic M. Role of F-choline PET/CT in evaluation of patients with prostate carcinoma. Radiol Oncol 2011; 45: 17-21.10.2478/v10019-010-0050-8Search in Google Scholar

Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002; 4: 267-73.10.1016/S1536-1632(02)00015-XSearch in Google Scholar

Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [11C] Choline uptake with PET/CT for initial diagnosis of prostate cancer: relation to PSA levels, tumour stage, and antiandrogenic therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1065-73.10.1007/s00259-008-0716-2Search in Google Scholar

Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F] fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169: 1337-40.10.1097/01.ju.0000056901.95996.43Search in Google Scholar

Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymphy-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52: 423-9.10.1016/j.eururo.2007.03.032Search in Google Scholar

Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T, Weirich G, et al. [11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Bio 2008; 35: 689-95.10.1016/j.nucmedbio.2008.05.006Search in Google Scholar

Reske SN, Blumstein NM, Glatting G. [11C]Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J NuclMol Imaing 2008; 35: 9-17.10.1007/s00259-007-0530-2Search in Google Scholar

Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005; 46: 1642-9.Search in Google Scholar

Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 6: 990-5.Search in Google Scholar

Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27: 1415-9.10.1007/s002590000309Search in Google Scholar

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002; 42: 18-23.10.1016/S0302-2838(02)00129-XSearch in Google Scholar

Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 2006; 47: 1642-9.Search in Google Scholar

Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, et al. Kinetics of [(11)C] choline uptake in prostate cancer: a PET study. Eur J Nucl Mol Imaging 2004; 31: 317-24.10.1007/s00259-003-1377-914628097Search in Google Scholar

Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T, et al. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Mol Imaging 2005; 32: 724-8.10.1007/s00259-004-1755-y16052370Search in Google Scholar

Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, et al. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005; 32: 668-73.10.1007/s00259-004-1741-415765234Search in Google Scholar

Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, et al. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009; 50: 1585-93.10.2967/jnumed.109.063396Search in Google Scholar

Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-65.10.1016/S0094-0143(05)70163-4Search in Google Scholar

Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF Jr. Gleason grading of prostate cancer: a predictor of survival. Urology 1985; 25: 223-7.10.1016/0090-4295(85)90316-4Search in Google Scholar

Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003; 62(Suppl 1): 19-35.10.1016/j.urology.2003.10.007Search in Google Scholar

Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005; 41: 858-87.10.1016/j.ejca.2004.12.035Search in Google Scholar

Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009; 100: 888-93.10.1038/sj.bjc.6604951Search in Google Scholar

Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, et al. Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 2010; 28: 687-92.10.1007/s00345-009-0471-4Search in Google Scholar

Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesisi correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997; 79: 772-9.10.1002/(SICI)1097-0142(19970215)79:4<772::AID-CNCR14>3.0.CO;2-XSearch in Google Scholar

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.10.1126/science.3798106Search in Google Scholar

Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, et al. Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003; 9: 1087-97.Search in Google Scholar

Savinainen KJ, Saramäki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002; 160: 339-45.10.1016/S0002-9440(10)64377-5Search in Google Scholar

Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000; 92: 1918-25.10.1093/jnci/92.23.191811106683Search in Google Scholar

Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. ClinCancer Res 2006; 12: 123-30.10.1158/1078-0432.CCR-05-144516397033Search in Google Scholar

Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010; 16: 1553-60.10.1158/1078-0432.CCR-09-254620179235Search in Google Scholar